Key facts
- Aquilon’s last known valuation is $6.9M (Aug 2019).
- It has raised $6.9M; the latest was PE Growth/Expansion in Mar 2026.
- Notable investors include European Innovation Council, European Union, Clave (Pamplona), Alentia Capital Alternativo, Adelaide Research and Innovation — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Aquilon
- ·The full record, as it builds
Funding rounds
No funding rounds for Aquilon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aquilon
Provider of veterinary services and products intended to develop autovaccines against swine dysentery. The company offers veterinary services and products that combat intestinal and respiratory diseases, enabling the porcine families to stay fit and healthy and build immunity to critical diseases.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Leon, Spain
- Founded
- 2012
- Employees
- 8
- Website
- aquiloncyl.com/
- Ownership
- Privately Held (backing)
Aquilon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aquilon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aquilon in its N-PORT filings yet. We sweep new filings monthly.